CAS: 4271-30-1; (S)-2-(4-Aminobenzamido)Pentanedioic Acid

相似化合物

5959-18-2 4271-30-1 6758-40-3

上下游产品

p-Nitrobenzoyl-L-(+)-glutamic acid diethyl N-(p-aminobenzoyl)-L-glutamate dimethyl p-trifluoroacetamidobenzoyl-L-glutamate (S)-2-(4-(((2-amino-4-hydroxypteridin-6-yl)methyl)amino)benzamido)pentanedioic acidN-{4-[(4-amino-2-thioxo-1,2-dihydro-pteridin-6-ylmethyl)-amino]-benzoyl}-L-glutamic acidN-{4-[(4-amino-2-thioxo-1,2-dihydro-pteridin-6-ylmethyl)-amino]-benzoyl}-L-glutamic acid N-{4-[(2,4-dioxo-1,2,3,4-tetrahydro-pteridin-6-ylmethyl)-amino]-benzoyl}-L-glutamic acidN-{4-[(2,4-dioxo-1,2,3,4-tetrahydro-pteridin-6-ylmethyl)-amino]-benzoyl}-L-glutamic acid folic acid N-((Ξ)-9-methyl-pteroyl)-L-glutamic acidN-((Ξ)-9-methyl-pteroyl)-L-glutamic acid

Folate 以 水 作为反应溶剂,化学反应生成 N-(4-氨基苯甲酰)-L-谷氨酸
参考文献:蝶呤杂质对市售叶酸的荧光和光化学的影响.
标题:蝶呤杂质对市售叶酸的荧光和光化学的影响.
摘要:叶酸或蝶氨-1-谷氨酸(pteglu)是一种共轭蝶呤衍生物,可在膳食中用作叶酸的来源,叶酸是人类多种生理功能所必需的一组化合物.pteglu的光化学很重要,因为叶酸不是由哺乳动物合成的,会经历光降解,其缺乏与许多疾病有关.我们已经证明,通常的商业pteglu不能通过未结合的氧化蝶呤6-甲酰基蝶呤(fop)和6-羧基蝶呤(cap)纯化.这些化合物的含量如此之低,以致于正常的色谱对照无法检测到任何蝶形污染.但是,Pteglu溶液的荧光是由于fop和cap的发射引起的,而pteglu发射的贡献要低得多,可以忽略不计.这是因为与fop和cap的φf相比,Pteglu的荧光量子产率(φf)非常弱.同样,Pteglu在uv-A辐射下的光降解是一种通过溶液中存在的氧化未结合的蝶呤对光敏化的氧化,而不是由pteglu直接吸收光子引发的过程.简而言之,使用市售固体制备的pteglu溶液的荧光和光化学性质是由
DOI:10.1016/j.Jphotobiol.2018.03.007

专利信息

专利号:US-5350851-A
优先权日:1992-03-16
标题 :Intermediates and a process for synthesis of tetrahydropteridine C6-stereoisomers, including (6S)-tetrahydrofolate and N5-formyl-(6S)-tetrahydrofolate
发明人：BAILEY STEVEN W; AYLING JUNE E
权利人:UNIV SOUTH ALABAMA
摘要:Intermediates and a process for the synthesis of 6-monosubstituted tetrahydropteridine C6-stereoisomers, including (6S)-tetrahydrofolic acid. The intermediates are shown in their two enantiomeric forms as follows: ##STR1## wherein R 1 and R 2 are the same or different and represent hydrogen, methyl, hydroxy, amino, alkyl or dialkylamino, alkoxy, benzyloxy, or benzylthio; R 3 represents an alkene, alkyne, cycloalkyl, benzyl, alkyl (substituted with hydroxy, acetoxy, benzyloxy, alkoxy, alkylthio, amino, carboxy, oxo, or phosphate), a protected aldehyde, or ##STR2## wherein n=1 or 2, R 4 is hydrogen, formyl, methyl, or propargyl, and ZZ represents an amino acid or amino acid polymer.

专利号:US-2023037284-A9
优先权日:2018-11-30
标题:Combination therapy of peptidomimetic macrocycles
发明人：GUERLAVAIS VINCENT; ANNIS DAVID ALLEN
权利人:AILERON THERAPEUTICS INC
摘要:The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.

专利号:US-4080325-A
优先权日:1976-11-17
标 题 :Synthesis of methotrexate
发明人：ELLARD JAMES A
权利人:US HEALTH EDUCATION & WELFARE
摘要:The present invention consists of three process improvements in the so-called multi-step Piper-Montgomery process designed especially to produce the antifolate methotrexate which is closely related to both aminopterin and folic acid. 2,4,5,6-tetraaminopyrimidine sulfite is one starting material and is usually produced in the form of the bisulfite in an acetate buffer. The present modification positively produces the hydrochloride from the bisulfite and eliminates the acetate buffer utilized in prior art processes. Subsequently, a pteridine ring is formed from the pyrimidine hydrochloride using dihydroxyacetone at pH 5.5±0.2 to form the second ring. This strict pH control together with the use of hydrochloride salt minus the acetate buffer assists in preferentially favoring the formation of 2,4-diamino-6-hydroxymethylpteridine. Subsequently the 6-hydroxy-methyl compound is converted to the hydrobromide acid salt and reacted with three moles of a triphenyl dibromophosphorane and phosphazine protecting groups are formed on the amine groups of the pteridine ring as the 6-hydroxymethyl group is transformed to 6-bromomethyl, a key intermediate. The present process leaves the protecting phosphazine groups on the primary amino groups to discourage side reactions during subsequent alkylation of the other major reactant, ethyl N-(p-methylaminobenzoyl)-L-glutamate. Furthermore, ethyl N-(p-methylaminobenzoyl)-L-glutamate, the other reactant, is uniquely produced for the present multi-step reaction by a process proceeding from ethyl N-(p-trifluoromethylaminobenzoyl)-L-glutamate by utilizing an alkali metal hydroxide in a lower (C 1 -C 6 ) alkanol wherein the protective trifluoroacetyl groups are removed. This step uses a special mixture preferably of an alkali metal hydroxide in ethanol and optimally 1 equivalent of KOH in 20% ethanol at or below ambient temperature where the mixture is added slowly to keep the reaction pH below 9. The combination of these improvements results in the increase of an overall yield of methotrexate from the named starting reactants from about 25% to approximately 40-50%.

专利号:US-2018371021-A1
优先权日:2017-05-11
标 题 :Peptidomimetic macrocycles and uses thereof
发明人：AIVADO MANUEL; GUERLAVAIS VINCENT; OLSON KAREN
权利人:AILERON THERAPEUTICS INC
摘要:The present disclosure describes the synthesis of peptidomimetic macrocycles and methods of using peptidomimetic macrocycles to treat a condition. The present disclosure also describes methods of using peptidomimetic macrocycles in combination with at least one additional pharmaceutically-active agent for the treatment of a condition, for example, cancer.

专利号:US-2011245484-A1
优先权日:2010-03-31
标 题 :Stereoselective synthesis of phosphorus containing actives

专利号:KR-20090049001-A
优先权日:2007-11-12
标 题:Synthesis of itrconazole antifungal derivatives and used it by derivatives of p-aminobenzoyl-l-glutamic acids